| Document Date: 2013-09-04 07:10:51
Open Document File Size: 337,88 KBShare Result on Facebook
City METABOLISM LEXINGTON / Barcelona / / Company Synageva BioPharma Corp. / / Country Spain / / / Event FDA Phase / / IndustryTerm biopharmaceutical company developing therapeutic products / drug product / manufacturing platform / / MedicalCondition Mucopolysaccharidosis IIIB / early onset LAL Deficiency / accelerated atherosclerosis / rare diseases / disease / cholelithiasis / liver failure / rare autosomal recessive lysosomal storage disease / acute cholecystitis / dyslipidemia / cirrhosis / Cholesteryl Ester Storage Disease / Lipase (LAL) Deficiency / MPS IIIB The mucopolysaccharidoses / acid lipase deficiency / portal hypertension / Wolman disease / diseases / diarrhea / INBORN ERRORS OF METABOLISM / deficiency / advanced liver disease / liver disease / LAL Deficiency / B syndrome / / MedicalTreatment enzyme replacement therapy / biologic therapies / liver transplant / / Organization European Medicines Agency / INTERNATIONAL CONGRESS / U.S. Food and Drug Administration / Ministry of Health / / Person MPS IIIB / Matthew Osborne / / / Position animal model / / Product SBC-103 / LAL / / ProvinceOrState Massachusetts / / Technology alpha / antibodies / / URL www.synageva.com / /
SocialTag |
SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA AT THE INTERNATIONAL CONGRESS OF INBORN ERRORS OF METABOLISM LEXINGTON, Mass., September 4, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company dev